Alcohol consumption in metabolic dysfunction-associated steatotic liver disease (MASLD): understanding the gut–liver crosstalk for clinical translation

These results indicated that the microbiota‒gut‒liver axis plays a crucial role in the progression of SLD intensified by alcohol and concurrent metabolic risk factors, thus providing a promising translational target for potential therapeutic interventions.

Authors

Institutions

Publication Details

Journal
Gut Microbes
Published
2026-02-21
DOI
https://doi.org/10.1080/19490976.2026.2631834
Citations
1
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
31.52
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Alcohol consumption in metabolic dysfunction-associated steatotic liver disease (MASLD): understanding the gut–liver crosstalk for clinical translation

Alexander Tyakht, Christian Liedtke, Rubén Francés, Francisco Javier Cubero et al.
1 citations
Gut Microbes
Liver Disease Diagnosis and Treatment
31.52
article

Alcohol consumption in metabolic dysfunction-associated steatotic liver disease (MASLD): understanding the gut–liver crosstalk for clinical translation

Alexander Tyakht, Christian Liedtke, Rubén Francés, Francisco Javier Cubero, Oriol Juanola, Nicole Treichel, M. Ávila, José M. Herranz, Rana Acar, J. L. Gilarranz Vaquero, Salvador Iborra, Alejandro H. Gutierrez, Özlen Konu, Marina S. Mazariegos, Hector Leal-Lassalle, Vera E. Odintsova, Rafael Bañares, Olga Estévez-Vázquez, Raquel Benedé-Ubieto, Andreea Ciudin, Tony Bruns, J Reißing, Ana Redondo-Urzainqui, Beatriz Gómez-Santos, Busra Korkmaz, Patricia Aspichueta, Justina Clarinda Wolters, Carlos Sanz-García, Yulia A. Nevzorova, Gulcin Cakan-Akdogan, Zehra Firat, Gonzalo Jorquera, Merve Basol
article en
1 citations

Abstract

These results indicated that the microbiota‒gut‒liver axis plays a crucial role in the progression of SLD intensified by alcohol and concurrent metabolic risk factors, thus providing a promising translational target for potential therapeutic interventions.

Gut MicrobesVol. 18(1)
Universitat de Miguel Hernández d'Elx (ES), Universidad Complutense de Madrid (ES), Hebron University (PS), University Medical Center Groningen (NL), Valparaiso University (US), Bilkent University (TR), University of the Basque Country (ES), University of Groningen (NL), Hyundai Mobis (South Korea) (KR), Lund University (SE), Dokuz Eylül University (TR), Hospital General Universitario Gregorio Marañón (ES), Lusaka Apex Medical University (ZM), BioCruces Health research Institute (ES), Vall d'Hebron Institut de Recerca (ES), DWI – Leibniz Institute for Interactive Materials (DE), Inmunotek (Spain) (ES), Centro Científico Tecnólogico - Rosario (AR), Navarre Institute of Health Research (ES), Centro de Investigación Biomédica en Red (ES), Vall d'Hebron Hospital Universitari (ES), Spanish National Centre for Cardiovascular Research (ES), Research Network (United States) (US), Max Planck Institute for Biology (DE), University of Chile (CL), International Institute for Strategic Studies (US), University of Valparaíso (CL), Universidad de Navarra (ES), RWTH Aachen University (DE)
Good health and well-being
Openalex Percentile: Top 1%
Liver Disease Diagnosis and Treatment
31.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.